Teclison Email Format
Biotechnology ResearchNew Jersey, United States2-10 Employees
Teclison is a biotechnology research company focused on developing cancer therapies that trigger tumor necrosis and enhance anti-tumor immunity to support long-term remission. Its work centers on solid tumors with a tendency to metastasize to the liver, beginning with hepatocellular carcinoma and metastatic colorectal cancer, with plans to expand to additional liver-metastatic cancers. Based in Montclair, New Jersey, the company operates as a small team of specialists drawn from the pharmaceutical field. In January 2026, Teclison participated in the ASCO Gastrointestinal Cancers Symposium, indicating ongoing engagement with the clinical oncology community. Its approach aims to create high local concentrations of its therapeutic agent within tumors, driving targeted necrosis and re-educating the tumor environment to support immune-based cancer control.